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Differentiation of astrocytes from human stem cells
has significant potential for analysis of their role in
normal brain function and disease, but existing pro-
tocols generate only immature astrocytes. Using
early neuralization, we generated spinal cord astro-
cytes from mouse or human embryonic or induced
pluripotent stem cells with high efficiency. Remark-
ably, short exposure to fibroblast growth factor 1
(FGF1) or FGF2 was sufficient to direct these astro-
cytes selectively toward a mature quiescent pheno-
type, as judged by both marker expression and
functional analysis. In contrast, tumor necrosis factor
alpha and interleukin-1b, but not FGFs, induced
multiple elements of a reactive inflammatory pheno-
type but did not affect maturation. These phenotypi-
cally defined, scalable populations of spinal cord
astrocytes will be important both for studying normal
astrocyte function and for modeling human patho-
logical processes in vitro.INTRODUCTION
Astrocytes play multiple roles in the central nervous system
(CNS). Many of these are critical to normal function in the healthy
adult, where astrocytes act as support cells for neurons, regu-
lating cerebral blood flow, energy reserves, and neurogenesis
(Abbott, 1988; Allaman et al., 2011; Lie et al., 2005; Okamoto
et al., 2011; Takano et al., 2006). Moreover, their involvementCell Rein synaptic transmission and plasticity has been the object of
intensive study (Bernardinelli et al., 2011; Panatier et al., 2011).
Cell culture models used to study normal astrocyte function
should therefore reflect this mature, quiescent phenotype.
However, astrocyte phenotypes are extremely dynamic.
Reactive phenotypes can be induced by proinflammatory
factors, such as tumor necrosis factor alpha (TNFa), interleukin
(IL)-1b, and interferon gamma, in a wide variety of traumatic
and pathological contexts (Gwak et al., 2012). Indeed, multiple
classes of reactive astrocytes can be identified, depending on
the nature of activating stimulus and the time elapsed postacti-
vation (Zamanian et al., 2012). Astrocyte activation leads to
production of a wide array of mediators, including chemokines,
inflammatory cytokines, and growth factors (Allaman et al.,
2011), as well as transcriptional changes of genes associated
with cell-to-cell communication (e.g., connexins), cytoskeletal
structure (e.g., glial fibrillary acidic protein [GFAP]), and many
others (for review, see Sofroniew [2009]). It is therefore essential
to precisely model the reactive state for in vitro studies of human
disease.
Human astrocytes have been cultured from fetal or adult post-
mortem CNS using expansion of neural precursors (Caldwell
et al., 2001; Haidet-Phillips et al., 2011; Lee et al., 1993; Verwer
et al., 2007), but such preparations are rare and intrinsically
variable. One of the first protocols to report differentiation of
human embryonic stem cells (hESCs) into astrocytes was that
of Krencik et al. (2011). However, one practical drawback of the
method is that it necessitates 6 months of culture to generate a
sufficiently pure population (Krencik et al., 2011; Krencik and
Zhang,2011).Since then,otherprotocols starting fromneural pre-
cursor cells have reported generation of astrocytes within 35–
80 days (Emdad et al., 2012; Juopperi et al., 2012; Lafaille et al.,ports 4, 1035–1048, September 12, 2013 ª2013 The Authors 1035
2012; Serio et al., 2013; Shaltouki et al., 2013). However, by the
criteria discussed below, the astrocytes generated in each case
are immature and do not fully model normal astrocyte function.
Astrocyte maturation occurs through a complex series of
events that remain incompletely understood. There is consider-
able overlap between expression of different markers, and it is
likely that the precise sequence of their appearance varies
from one region of the CNS to another. Nevertheless, we have
constructed a tentative synthesis of the appearance of known
markers during maturation based on spinal cord data, where
available (Figure S1). Overall, astrocyte development and matu-
ration encompasses two phases (see Extended Results for full
review, abbreviations, and citations). During the first—mainly
embryonic—phase, subsets of astrocytes are generated from
radial glia and progressively take on their principal functional
phenotypes. Subsequently, over the first postnatal weeks in
rodents, astrocytes adopt a mature, quiescent morphology
and phenotype. Although all potential marker genes have not
been studied in parallel in a single brain region, the sequence
of appearance of markers during the first, embryonic phase is
likely NF1A > GLAST > ALDH1L1 > Cx43 > S100b > CD44 >
AldolaseC > GFAP. The NF1A+/GFAP+ cells generated by extant
stem cell differentiation protocols (see above) likely correspond
to this first, immature stage. In contrast, the second, matura-
tional phase is associated with downregulation of GFAP, GLAST,
and ALDH1L1, whereas GFAP expression persists in white
matter astrocytes. In parallel, there is continued accumulation
of Cx43, followed by Aqp4 and the mature astrocyte glutamate
transporter 1 (GLT1). Therefore, mature gray matter astrocytes
should not be expected to express high levels of GFAP, so other
markers are needed to monitor their maturation and purity.
To summarize, astrocytes may adopt either a quiescent state
with protoplasmic morphology, characterized by low GFAP and
high GLT1, or a fibrous, reactive phenotype characterized by
high GFAP and low GLT1. Standard preparations of cultured
GFAP+ astrocytes (McCarthy and de Vellis, 1980) reflect only
the latter (Zamanian et al., 2012). Therefore, a robust model of
mature, quiescent astrocytes would be a significant step forward
for in vitro studies of human neural function as well as disease.
This is especially significant given the different effects of imma-
ture and mature astrocytes on axonal regeneration (Goldshmit
et al., 2012; Tom et al., 2004). Here, we report that, using identi-
fied signaling factors, mouse or human spinal cord astrocytes
generated from either ESCs or human induced pluripotent
stem cells (hiPSCs) can be induced to adopt phenotypes that
correspond to those of either mature or reactive astrocytes
in vivo. Such defined populations of mature human astrocytes
will considerably increase the resolution of studies of normal
astrocyte function, whereas fully activated preparations open
the door to more precise disease modeling based on patient-
derived hiPSCs.
RESULTS
Astrocytes Derived from Mouse Embryonic Stem Cells
Are Immature
Because the development and maturation of astrocytes are
better understood in rodents than in human, we first generated1036 Cell Reports 4, 1035–1048, September 12, 2013 ª2013 The Auastrocytes from mouse embryonic stem cells (mESCs). Our
overall aim was to generate astrocytes of spinal cord identity
as a tool for modeling motor neuron diseases, such as amyotro-
phic lateral sclerosis (ALS). We therefore used an induction
protocol that specifies ventral spinal progenitors (Wichterle
et al., 2002) followed by neurosphere expansion, which amplifies
neural progenitors and generates largely glial cells (Kuegler et al.,
2012; Figure S1; Experimental Procedures). After 1 week,
cultures of dissociated neurospheres contained cells that
stained for canonical markers of developing astrocytes: GFAP,
Aqp4, S100b, vimentin, and NF1A (Figures 1A and 1B), and their
spinal cord identity was confirmed by coexpression of HoxB4
(Figure 1A). The pluripotency marker Oct4 was undetectable
(Figure S2C), and neurons (bIII-tubulin+), microglia (Iba1+), and
oligodendrocytes (2030-cyclic-nucleotide 30-phosphodiesterase
[CNPase]+ or oligodendrocyte transcription factor 2 [Olig2]+)
were rare or absent (Figures 1B and S1D). The mESC-derived
cultures therefore contained essentially only astrocytes and glial
precursors. However, they were not homogeneous, because
many cells were not double stained for any given pair of antigens
(Figure 1A) and less than one-third of the cells positive for vimen-
tin and NF1A expressed themarkers Aqp4, S100b, or GFAP (Fig-
ure 1B). This is comparable to the heterogeneity in cultures of
neonatal astrocytes (Imura et al., 2006). Our data suggested
that the cultures contained developing astrocytes at different
stages of maturity.
To assess their state of maturation, we used western blots to
quantify levels of three markers known to be upregulated in
astrocytes as they mature: GLAST and ALDH1L1, which appear
at midembryogenesis, and GLT1, a postnatal marker (Figure 1C;
see Extended Results). Although 4 weeks had elapsed since the
mESCs were put into culture, and although GFAP was clearly
present, none of these markers could be detected. This was in
contrast to astrocytes generated from primary neural precursors
of embryonic day 12.5 (E12.5) spinal cords using a neurosphere-
based approach (Figure S2A), which expressed robust levels of
GLAST, ALDH1L1, and GLT1 (Figure 1C). We therefore sought
treatments through which mESC-derived spinal astrocytes
could be brought to a similar degree of maturity.
FGFs Promote Maturation of mESC-Derived Astrocytes
In vivo, fibroblast growth factors (FGFs) have been proposed to
act as differentiation signals for astrocytes (Irmady et al., 2011;
Morrow et al., 2001) and FGF1 is strongly expressed in postnatal
spinal neurons (Elde et al., 1991). Addition of FGF1 to mESC-
derived astrocytes from days 28–35 triggered a >4-fold increase
in the number of cells expressing GLT1, with an EC50 of 5 ng/ml
(Figures 2A and 2B). Similar results were obtained using FGF2 in
place of FGF1 (Figure S3). Western blotting confirmed that FGF
increased overall levels of both GLT1 and GLAST (Figures 2C,
2D, and S3C) as well as other maturation markers, such as
aldolase C, Cx43, and ALDH1L1 (Figures 2D and S3C). In
parallel, GFAP levels were strongly downregulated (Figures 2B,
2D, S3A, and S3C). Thus, mESC-derived cultures treated with
FGFs express high levels of glutamate transporters and low
GFAP, a phenotype reminiscent of mature quiescent astrocytes.
To determine whether this biochemical maturation resulted in
functional changes, we measured glutamate uptake, a key rolethors
Figure 1. Mouse ESC-Derived Spinal Cord Astrocytes Show an Immature Phenotype
(A) Differentiated mESC cultures contain glial cells expressing canonical astrocyte markers together with the spinal cord marker HOXB4. Insets show higher
magnification of regions indicated with dotted lines. The scale bars represent 75 mm.
(B) Percentages of mESC-derived glial cells expressing markers for astroglia (Aqp4, S100b, vimentin, NF1A, and GFAP), oligodendroglia (Olig2 and CNPase),
neurons (b-III-tubulin), microglia (Iba1), and spinal cord identity (HOXB4). Mean ± SEM; n = 3–4 independent differentiations.
(C) Western blot of mESC-derived astrocytes as compared to astrocytes derived from E12.5 mouse embryo spinal cord. GFAP protein is present in both, but
ALDH1L1, GLAST, and GLT1 are only detectable in the mE12.5-derived astrocytes. a-tubulin was used as loading control.
See also Figure S2.of mature astrocytes (Huang and Bergles, 2004). In mESC astro-
cytes from two different cell lines grown in fetal bovine serum
(FBS) alone, we detected significant levels of glutamate uptake
that were Na+-dependent, as expected (Figure 2E; Mitani and
Tanaka, 2003; Rothstein et al., 1996). Exposure to FGF1 for
7 days led to a 2-fold increase in glutamate transport (Figure 2E),
reflecting upregulation of the transporters responsible (Figures
2B–2D). Thus, functional astrocytes can be efficiently generated
from mESCs and FGF1 promotes their biochemical and func-
tional maturation to a quiescent state.
Human Spinal Cord Astrocytes Derived from hESCs and
hiPSCs following Early Neuralization
We then used the findings with mouse ESCs to generate mature
human astrocytes. To accelerate astrocyte production, rather
than passing through a stage of cycling neural precursors (Shal-
touki et al., 2013), we turned to early neuralization by dual inhibi-
tion of SMAD signaling, which had been shown by Chambers
et al. (2009) to enhance production of CNS precursors and neu-
rons but whose effect on glial generation had not been studied.
To inhibit SMAD signaling, we employed the activin receptor-like
kinase 4 (ALK4)/ALK5/ALK7 inhibitor SB431542 together with
LDN193189, a potent derivative of dorsomorphin that inhibitsCell Retransforming growth factor b1/activin receptor-like kinase
(Boulting et al., 2011; Kriks et al., 2011; Yu et al., 2008).
We used one hESC line (R1; James et al., 2006) and one hiPSC
line (18c; Bock et al., 2011; Boulting et al., 2011) derived from a
healthy volunteer, which we have shown to have a strong pro-
pensity for neural differentiation. When SB431542 (10 mM) and
LDN193189 (0.2 mM) were added to cultures from 1 to 5 days
in vitro (DIV) (Figure 3A), 70%–80% of cells in the culture at 10
DIV were PAX6+ Oct4 neural progenitors (data not shown). To
direct the cells toward a caudal ventral identity, retinoic acid
(RA) and sonic hedgehog cysteine mutated (SHH-C) were
added, as indicated, and neurotrophic factors were provided
to support neuronal survival (Figure 3A). By 40 DIV, as with earlier
protocols (Hu et al., 2010; Karumbayaram et al., 2009; Li et al.,
2005; Shaltouki et al., 2013), the cultures were enriched for
markers of ventral neuronal populations (OLIG2, HB9, ISL1/
ISL2, NKX2.2, and NKX6.1; data not shown). Critically for our
studies, they showed spinal cord (HOXB4; >90%) but not
midbrain (OTX2; <2%) identity (Figure 3B). Early neuralization
did not, therefore, perturb the patterning of these neural
precursors.
Wemonitored the appearance of different cell classes over the
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Figure 2. FGF1 Promotes Maturation of mESC-Derived Astrocytes
(A) Effects of increasing dose of FGF1 on the relative abundance of GLT1-expressing astrocytes in mESC-derived cultures (mean ± SEM for two independent
experiments, three replicates per condition). One-way ANOVA reveals an effect of treatment above 5 ng/ml. p = 0.013; F(8;9) = 5.01. The asterisk denotes p < 0.05.
(B) Compared to an FBS control (left), 50 ng/ml FGF1 (right) triggers a strong increase in GLT1 staining and a nearly complete loss of GFAP immunoreactivity.
The scale bar represents 75 mm.
(C) Increased GLT1 expression following FGF1 treatment of astrocytes derived from two independent mESC lines (Hb9::GFP and wild-type) revealed by western
blot analysis. Results are representative of three independent experiments. WT, wild-type.
(D) FGF1 is sufficient to induce appearance of GLAST, CX43, and ALDH1L1 but strongly decreases GFAP expression. Results are representative of three
independent experiments.
(E) Na+-dependent L-(3H)-glutamate transport using twomESC lines differentiated into astrocytes shows an average 2-fold increase in uptake following treatment
with FGF1 (bars show mean ± SEM; n = 4; p = 0.0095; F(3;3) = 1.286. The double asterisks denote p < 0.01).
See also Figure S3.(H13) and hiPSC (11a) lines. Neurons were initially abundant at
early stages but disappeared over the period 30–60 DIV until,
by 90 DIV, there were no neurons remaining (Figure 3C). More-
over, few CNPase-positive oligodendrocytes could be detected
at either 40 or 90 DIV (<3%of total cells; Figure 3D), and whereas
many cells at early stages expressed the neural crest marker
p75, these too were spontaneously eliminated (data not shown).
GFAP staining was first observed from 20–45 DIV, in the form of
scattered GFAP+ and A2B5+ cells (Figure 3E; data not shown),
whose long processes suggested they might be radial glia
(Hirano and Goldman, 1988). Over the period 40–80 DIV, the
abundance of multipolar GFAP-expressing cells with the
HoxB4+/Otx2 profile characteristic of spinal cord increased
10-fold to >70% of DAPI-labeled cells (Figure 3F; data not
shown), and by 80 DIV, astrocyte markers CD44, S100b, CX43,1038 Cell Reports 4, 1035–1048, September 12, 2013 ª2013 The Auvimentin, NF1A, and aldolase C were all present in cultures
from each of the four hESC/hiPSC lines (Figures 3G–3J). Nearly
100% of the cells expressed the glial marker S100b (Figure 3F),
consistent with their homogeneous morphology (Figure S4).
We next analyzed the functional capacity of astrocytes derived
following early neuralization. Excitatory amino-acid transporter 2
(EAAT2) (equivalent to rodent GLT1) was already detectable in a
subset of cells (Figures 3I and 3J) and, accordingly, all human
astrocyte cultures exhibited a basal level of Na+-dependent
glutamate transport (Figure 4A). Mechanical stimulation of single
astrocytes from all four lines generated calciumwaves that prop-
agated to adjacent astrocytes (Figure 4B; data not shown).
Lastly, the astrocytes expressed both brain-derived neurotro-
phic factor (BDNF) and glial-cell-line-derived neurotrophic factor
(GDNF) and secreted factors that significantly enhanced survivalthors
and neurite outgrowth from fluorescence-activated cell sorting
(FACS)-purified human ESC-derived motor neurons (Figures
4C–4E). This correlates well with the growth-promoting activity
of immature astrocytes reported in vivo (Filous et al., 2010;
Goldshmit et al., 2012). Thus, early neuralization generates
human spinal cord astrocytes expressing many canonical
biochemical and functional traits.
Nevertheless, as with mESC cultures, maturation was less
than complete and varied between lines. For example, the glial
progenitor marker NF1A was strongly expressed in cultures
from all four lines (Figure 3J). Moreover, even among mature
markers, the populations derived from different stem cell lines
were not homogeneous. For example, EAAT2 expression was
consistently lower in the H13 hESC cultures, as shown by
immunocytochemistry and western blotting (Figures 3I and 3J).
We reasoned that this might reflect the absence of humoral
maturation factors that astrocytes normally encounter in vivo.
We therefore grafted 80- to 90-DIV hESC- and hiPSC-derived
astrocytes into the striatum of adult rats (Figure 4F; Brederlau
et al., 2006). After 2 and 7 weeks, staining for human nuclei in
four animals per line transplanted revealed that grafted cells in
all animals had survived (Figure S5). Survival in vivo is a charac-
teristic of immature astrocytes (Filous et al., 2010) and, accord-
ingly, at 7 weeks 86% ± 1% (mean ± SEM; n = 16; no significant
differences between lines or time points) of grafted cells were
GFAP+ and 88% ± 6% expressed NF1A (Figure 4G). The pres-
ence of these immature markers demonstrated that the in vivo
environment alone was not sufficient to induce quiescence and
may have indeed stimulated astrocyte reactivity.
FGFs but Not TNFa PromoteMaturation of Human Stem-
Cell-Derived Astrocytes
We therefore tested candidate factors for their ability to promote
maturation, focusing on FGF1 because of the potent effects we
had found in the murine system. As a control, we used TNFa,
because it has been implicated in triggering astrocytosis in
neurodegenerative contexts (Cui et al., 2011) and was previously
shown to activate primary human astrocytes in vitro (Croitoru-
Lamoury et al., 2003; Meeuwsen et al., 2003). Human ESC and
hiPSC lines were differentiated as above for 90 days and then
thoroughly washed to remove any residual FBS. They were sub-
sequently treated for 7 days with FBS (1% v/v), FGF1 (50 ng/ml),
or TNFa (50 ng/ml), the latter two factors in the absence of
serum. Although morphological changes were observed (Fig-
ure S4), levels of the canonical markers S100b and aldolase C
were not affected by these treatments (Figures 5A and 5B), sug-
gesting that the cells retained their astrocyte identity throughout.
In striking contrast, western blotting revealed that FGF1 induced
a nearly complete loss of expression of both GFAP and NF1A in
both cell lines, whereas cells treated with TNFa showed little
change in either marker (Figure 5B). Correspondingly, immuno-
staining for NF1A and GFAP was markedly reduced in the cell
aggregates induced by FGF1 (Figures 5C and S6). To exclude
the possibility that this might be a secondary effect of cell aggre-
gation, we performed the same experiments after dissociation of
cell clumps followed by replating. Similar reductions were
observed (Figures S6A and S6B), confirming that these are direct
effects of FGF. Another marker whose levels in human astro-Cell Recytes were significantly reduced by FGF1 as compared to FBS
was CX43 (Figure 5D). This is consistent with a more quiescent
phenotype following FGF treatment (Theodoric et al., 2012).
Although mESC-derived astrocytes treated with FGF showed
the opposite change (Figure 2D), Cx43 levels in rodents rise
during perinatal development (Dermietzel et al., 1989) and so
this change may reflect developmental maturation. Overall,
therefore, human astrocytes are induced to adopt a mature
quiescent phenotype by FGF1 but not by TNFa.
To confirm this conclusion, we assayed functional changes
triggered by each factor. Under pathophysiological conditions,
reactive inflammatory astrocytes express low levels of glutamate
transporters (Rothstein et al., 1995); this was potentially the case
with our FBS cultures, which are rich in GFAP+ astrocytes. In
agreement with this, FGF1 led to a 2-fold increase in Na+-depen-
dent glutamate transport activity. Similar effects were seen with
FGF2 (Figure S5E), whereas TNFa had no or even a negative ef-
fect (Figure 5E), as reported for primary astrocytes (Fine et al.,
1996). Unexpectedly, given the increased transport, FGF1
induced no marked changes in EAAT2 protein or messenger
RNA (mRNA) levels (Figures 5F and 5G). As an alternative expla-
nation for the increased glutamate transport, we investigated
EAAT1, a related transporter whose levels in gray-matter astro-
cytes in vivo also increase with postnatal age (Voutsinos-Porche
et al., 2003a, 2003b). We indeed observed a 4-fold increase in
EAAT1 levels following treatment with FGF1, whereas TNFa
had no effect (Figure 5H). Moreover, dihydrokainate (DHK) (an in-
hibitor of EAAT2 transport) had no effect on glutamate uptake
(Figure S5F), further supporting the involvement of EAAT1.More-
over, similar effects of FGF were seen in aggregated or dissoci-
ated cultures, suggesting that the increased glutamate transport
is not an indirect effect of cell clumping (Figure 5H). Overall, our
results show that FGF1 or FGF2 but not TNFa are sufficient to
induce a mature biochemical and functional phenotype in hu-
man, as in mouse, stem-cell-derived astrocytes.
TNFa and IL-1b, but Not FGF1, Trigger Reactivity of
Human Pluripotent-Stem-Cell-Derived Astrocytes
Because TNFa had proven inactive in driving astrocyte matura-
tion, we askedwhether it was able to induce astrocyte activation.
We monitored expression of the chemokines CXCL8 and
RANTES (also known as IL8 and CCL5, respectively), which
are strongly upregulated in human astrocyte primary cultures
treated with TNFa (Croitoru-Lamoury et al., 2003; Meeuwsen
et al., 2003), as well as expression of lipocalin-2 (LCN2) and
tissue inhibitor of metalloproteinase-1 (TIMP1), which were
recently shown to be upregulated in reactive astrocytes in vivo
(Zamanian et al., 2012). Within 2 days of TNFa administration,
levels of mRNA for CXCL8 and RANTES were increased >300-
fold over those for cells maintained in FBS (Figure 6A), whereas
7 days after TNFa treatment, LCN2 levels were also increased
(>1,000-fold in R1 and 8-fold in 18c astrocytes; Figure 6B).
Another proinflammatory cytokine, IL-1b, led to a 4,000-fold
increase in LCN2 (Figure S6F). In contrast, FGF1 induced a
modest downregulation in both chemokines and LCN2 (Figures
6A and 6B). TIMP1 mRNA levels did not change more than
8-fold in any condition (data not shown), suggesting that it is
less strongly regulated than LCN2 in cultured astrocytes. Thus,ports 4, 1035–1048, September 12, 2013 ª2013 The Authors 1039
(legend on next page)
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TNFa induces a molecular phenotype that is consistent with
astrocyte reactivity.
To test this more directly, we measured the production of the
cytokine IL-6, which in primary astrocytes acts in an autocrine
manner to stimulate its own production (Van Wagoner et al.,
1999). No IL-6 could be detected in FBS control cultures or in
cells treated with FGF1 (Figure 6C). In marked contrast, TNFa
led to an increase in IL-6 production that was already detectable
after 1 day and increased to >300 pg/ml after 1 week (Figure 6C).
Similarly strong responses to TNFa were observed in astrocytes
generated from another hESC line (H13) and three other hiPSC
lines (11a, 25b, and 39d; data not shown), and IL-1b produced
similar effects (Figure S6). Therefore, both TNFa and IL-1b
induce a reactive phenotype.
Overall, our data show that single factors can rapidly modify
the phenotype of pluripotent-stem-cell-derived astrocytes in
distinct and biologically relevant manners (Figures 6D and S6H).
DISCUSSION
The role of astrocytes in vivo varies widely according to their
degree of developmental maturation or reactivity and potentially
their regional specificity, yet the distinction between these func-
tional states has not been clearly established in in vitro models.
Having generated human spinal cord astrocytes from hESCs or
hiPSCs through early neuralization, we focused on biochemical
and functional characteristics that distinguish quiescence from
reactivity in the animal and used them to definemethods through
which each state can be selectively enhanced in culture. Strik-
ingly, we found that single factors were sufficient to promote
such transitions: FGF1 or FGF2 are sufficient to strongly enhance
maturation/quiescence without triggering inflammatory pheno-
types, whereas TNFa or IL-1b produces the converse effect.
Our data show clearly how exogenous factors can modify astro-
cyte functional status, and they provide a means of generating
human patient-derived astrocytes that are functionally homoge-
neous for future studies of development or of disease.
One of the challenges in using human pluripotent stem cells for
either basic or translational biology is the length and consequentFigure 3. Rapid Generation of Spinal Cord Astrocytes from hESCs and
(A) Treatments used for efficient generation of hESC- and hiPSC-derived astrocyte
supplement; B27, B27 supplement; NTFs, neurotrophic factors (CNTF, BDNF, IG
(B) Efficient conversion of human pluripotent stem cells—here shown for hESC
independent experiments. The scale bar represents 50 mm.
(C) At 80 DIV, no neurofilament (NF-H)-expressing neurons are found in hESC- a
NF-H-expressing cells was 40% (data not shown). The scale bar represents 75
(D) At 80 DIV, very few CNPase-expressing oligodendrocytes are detected. M
represents 50 mm.
(E) At 45 DIV, GFAP-expressing cells display bipolar morphology and resemble r
(F) At 90 DIV, cultures are enriched in GFAP-expressing astrocytes, which retain
3–4). The scale bar represents 50 mm.
(G) At 80 DIV, hESC- and hiPSC-derived cultures (here shown for R1) contain abu
The scale bar represents 50 mm.
(H) The number of cells expressing the canonical astrocyte marker S100b in
represents 50 mm.
(I) At 80 DIV, hESC- and hiPSC-derived cultures (R1 and 18c) contain astrocyte
abundance ± SEM (n = 3–5 independent differentiations). The scale bar represen
(J) Western blotting confirms the expression of the astroglial markers in all lines te
representative of two independent experiments.
Cell Revariability of the protocols needed to generate specific cell types
(Krencik and Zhang, 2011). One approach to the acceleration of
protocols for astrocyte generation used in several recent publi-
cations is based on the initial generation of neural precursors,
in some cases involving manual picking of rosettes (Emdad
et al., 2012; Juopperi et al., 2012; Lafaille et al., 2012; Serio
et al., 2013; Shaltouki et al., 2013). Given our interest in motor
neuron biology and disease, we instead began by early neurali-
zation of monolayer cultures followed by caudalization and
ventralization, which we and others have shown to generate spi-
nal neurons with high yield in shorter times (Amoroso et al., 2013;
Boulting et al., 2011; Chambers et al., 2009). Our method al-
lowed spinal cord astrocytes with the expected molecular and
functional characteristics to be generated in half the time (80–
90 days as compared to 180 days) needed for neurosphere-
based approaches (Gupta and Kanungo, 2013; Krencik et al.,
2011). However, as with all other protocols published to date,
the astrocytes were immature, as judged by bothmarker expres-
sion and glutamate uptake aswell as other traits, such as survival
after transplantation.
We found that both FGF1 and FGF2 are capable of inducing a
mature, quiescent astrocyte phenotype characterized by low
GFAP and NF1A but high levels of glutamate transport. Our find-
ings are distinct from other reported effects of FGFs in vitro but
closely match developmental in vivo data. In vitro, FGFs have
been reported to induce mitosis (Lin and Goldman, 2009) and
gap junction coupling (Garre´ et al., 2010) but not maturation.
Particularly striking are the divergent reports of responses to
FGFs. Some studies report induction of stellate morphology
(Cassina et al., 2005; Reilly et al., 1998) and even increased
GFAP immunostaining (Cassina et al., 2005), whereas others
observe dedifferentiation and adoption of a bipolar morphology
(Goldshmit et al., 2012). It is likely that the different outcomes
reflect the presence of different astrocyte subtypes or culture
conditions. In vivo, FGFR3, which can be activated by both
FGF1 and FGF2 (Chen and Hristova, 2011; Ornitz et al., 1996),
is expressed specifically by astrocytes and their precursors in
postnatal spinal cord (Pringle et al., 2003). Strikingly, in null
mutant mice for FGFR3, there is a strong upregulation of GFAPhiPSCs following Early Neuralization
s. P, passage; LDN, LDN193189; SB, SB431542; ASAC, ascorbic acid; N2, N2
F-1, GDNF).
(R1) line—into HOXB4+ OTX2 spinal cord cultures. Representative of three
nd hiPSC-derived cultures (here shown for line 18c). At 40 DIV, the fraction of
mm.
ean abundance ± SEM (n = 2–3 independent differentiations). The scale bar
adial glia. The scale bar represents 50 mm.
their spinal cord identity, as revealed by HOXB4 expression (mean ± SEM; n =
ndant astrocytes that express the canonical marker CD44 (mean ± SEM; n = 2).
creases over time to nearly 100% (mean ± SEM; n = 2–3). The scale bar
s that express canonical markers together with the EAAT2 transporter. Mean
ts 75 mm.
sted. Human adult spinal cord (HASC) tissue was used as positive control. Blot
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in spinal gray-matter from 2months of age onward, and signaling
through FGFR3 can repress GFAP (Pringle et al., 2003). In
agreement with our findings, this suggests that FGFs drive and
maintain a quiescent mature phenotype in vivo. In FGF2-null
mutants, in apparent contrast, GFAP is reduced in spinal gray
matter, but this was suggested by the authors to reflect an early
developmental role for FGF2 (Irmady et al., 2011). Therefore,
treatment of immature pluripotent stem-cell-derived astrocytes
with FGF1/FGF2 is an effective and physiologically relevant
means for inducing in vitro maturation.
Astroglial activation is associated with several nervous system
pathologies (Glass et al., 2010). Focusing on motor neuron dis-
ease, specific astrocyte reactivity is observed inpostmortemcor-
tex and spinal cord of ALSpatients (Kamo et al., 1987;Murayama
et al., 1991; Schiffer et al., 1996) and inflammatory gene expres-
sion is upregulated in astrocytes derived from sporadic ALS pa-
tients (Haidet-Phillips et al., 2011). GFAP and ALDH1L1 are upre-
gulated following injury and in the ALS spinal cord (Anthony and
Heintz, 2007; Yang et al., 2011), and a dramatic loss of GLT1 is
observed in other pathological situations (Chao et al., 2010; Fai-
deau et al., 2010; Rothstein et al., 1995). For reliable disease
modeling, it is therefore essential to reproduce the reactive state.
We found that TNFa induces, in human stem-cell-derived astro-
cytes, a phenotype characterized by high GFAP and production
of inflammatory chemokines andcytokines, aswell as very strong
upregulation of Lcn2, the top gene in the list of markers shown by
Zamanian et al. (2012) to be upregulated in two different models
of reactivity. This is of particular interest, because Lcn2 was
recently reported to trigger neuronal death and to contribute to
astrocyte toxicity (Bi et al., 2013). In parallel experiments, we
extensively tested the effects of other potential activators. For
example, IL-1b elicited several characteristic signatures of acti-
vation but also promotedGLAST expression, amarker ofmatura-
tion (data not shown). Opposite effects of TNFa and IL-1b on
astrocytes have previously been reported (Sokolova et al.,
2012). We therefore recommend, for standard differentiations,
the use of the more selective activator TNFa.
The two populations of astrocytes we have generatedwill have
multiple uses. We report that human stem-cell-derived astro-
cytes are capable of an immunological response similar to that
evoked by cytokines in primary human astrocytes (MeeuwsenFigure 4. Human Stem-Cell-Derived Astrocytes Are Functional but No
(A) All hESC- and hiPSC-derived astrocytes show Na+-dependent L-(3H)-glutam
performed).
(B) Mechanical stimulation (white arrow) of a single astrocyte induces a wav
represents 75 mm.
(C) Whole-well imaging of hESC-derived motor neurons live-stained with calcein f
factors (NTF). Green images show selected fields. The scale bars represent 200
(D) Human astrocytes enhance survival and growth of hESC-derived motor neu
motor neuron survival, P and F values are: no NTF versus astrocyte coculture: p
NTF: p = 0.0239, F(4;9) = 4.79. For neurite outgrowth, P and F values are: no NTF
supplemented with NTF coculture: p = 0.0045, F(4;9) = 8.19. The asterisk denote
significant differences.
(E) qPCR analysis shows that hESC- and hiPSC-derived astrocytes express BDN
indicate SEM for n = 3 independent experiments (all in duplicate).
(F) hESC- and hiPSC-derived astrocytes do not form teratomas in the striatum of
scale bars represent 250 mm and 50 mm.
(G) Even at 7 weeks posttransplantation, human ESC- and hiPSC-derived astrocy
See also Figures S4 and S5.
Cell Reet al., 2003), and this should be important for modeling human
pathological processes in vitro. Mature, quiescent astrocytes
will clearly be important for studying normal function but may
also be relevant to disease conditions. In vitro, astrocytes from
mutant superoxide dismutase 1 (SOD1) mouse models of ALS
release toxic factors for motor neurons (Di Giorgio et al., 2007;
Nagai et al., 2007). Accordingly, in vivo, reduction of SOD1 levels
in GFAP+ (and therefore reactive) cells leads to an increase in
survival of the mice (Yamanaka et al., 2008). This might suggest
that the reactive, GFAP+ astrocytes are the principal contributors
to toxicity for motor neurons. However, astrocytes lacking SOD1
retained GFAP expression, although they were less toxic (Yama-
naka et al., 2008). Therefore, astrocyte toxicity and reactivity can
be uncoupled. Thus, in assaying the contribution of astrocytes to
pathology in vivo, it is critical to evaluate even mature, quiescent
populations. Moreover, for modeling neurodegenerative disease
in vitro, it will be essential to distinguish between the effects of
mature and activated astrocytes, and our protocol provides a
means of doing this using both rodent and human cells.
EXPERIMENTAL PROCEDURES
Differentiation of Spinal Cord Astrocytes from Mouse and Human
Pluripotent Stem Cells
Rodent motor neuron cultures were dissociated into single-cell suspension
and grown in neurosphere (NS) medium supplemented with FGF2 and
epidermal growth factor. Neurospheres were dissociated, and single cells
were seeded onto 100 mg/ml poly-L-ornithine and 15 mg/ml laminin-coated sur-
faces in NS medium supplemented with 10% FBS. Neuralized human motor
neuron cultures (aged 31 DIV) were passaged onto 100 mg/ml polyornithine
and 3–5 mg/ml laminin-coated surfaces in NS medium supplemented with
1% FBS. Rodent and human cultures were passaged when they reached con-
fluency. The presence of astrocytes was detected by immunocytochemistry.
All human iPSC lines were derived from anonymized human skin biopsies
following approval by the Columbia University Institutional Review Board.
RNA Isolation and Quantitative PCR
The total RNA was isolated from cultured cells with RNeasy Kit (QIAGEN).
Complementary DNA (cDNA) was generated using the Verso TM cDNA Kit
and was used as template for the quantitative PCR (qPCR).
Measurement of Glutamate Uptake
Cells were incubated for 5 min at 37C in Na+ buffer containing 0.5 mML-gluta-
mate and 0.3 mCi L-[3H]-glutamate per sample. Cells were then lysed with 0.1Nt Completely Mature
ate transport activity (SEM shown for n = 3 independent experiments were
e of calcium influx that propagates to adjacent astrocytes. The scale bar
ollowing coculture with astrocytes in the presence or not of exogenous growth
mm (top) and 75 mm (bottom).
rons following coculture. One-way ANOVA reveals an effect of treatment. For
= 0.0224, F(4;8) = 5.25 and NTF versus astrocyte coculture supplemented with
versus astrocyte coculture: p = 0.0221, F(4;8) = 5.38 and NTF versus astrocyte
s p < 0.01 and double asterisks denote p < 0.001, which denote statistically
F and GDNF at levels comparable to or greater than HASC tissue. Error bars
adult rats, even at 7 weeks posttransplantation, revealed by Nissl staining. The
tes maintain an immature/reactive phenotype. The scale bar represents 50 mm.
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Figure 5. FGF but Not TNFa Triggers Biochemical and Functional Maturation of Human Stem-Cell-Derived Astrocytes
(A) Astroglial purity at 90 DIV; virtually all cells express S100b in all conditions. The scale bar represents 50 mm.
(B) Dramatic reduction in GFAP and NF1A protein levels but not aldolase C following treatment with FGF1 at 80 DIV, whereas TNFa has little impact. a-tubulin was
used as loading control. Results are typical of three independent experiments.
(legend continued on next page)
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Figure 6. TNFa but Not FGF1 Triggers Reac-
tivity of hESC- and hiPSC-Derived Astro-
cytes
(A) Strong effects of TNFa but not FGF1 on
RANTES and CXCL8 expression (mean ± SEM;
n = 4 for R1 and n = 3 for 18c). One-way ANOVA
reveals an effect of treatment. P and F values are:
RANTES R1: p = 0.0002, F(2;6) = 46.99; RANTES
18c: p < 0.0001, F(2;6) = 111.7; CXCL8
R1: p = 0.0006, F(2;6) = 32.73; and CXCL8 18c:
p < 0.006, F(2;6) = 13.03. The asterisk denotes
p < 0.05, double asterisks denote p < 0.001,
and triple asterisks denote p < 0.0001,
which denote statistically significant differences
between treatments.
(B) hESC- and hiPSC-derived astrocytes strongly
express LCN2 after 7 days treatment with TNFa
but not with FGF1 (mean ± SEM; n = 3). One-way
ANOVA reveals an effect of treatment. P and F
values are: R1: p = 0.0076, F(2;6) = 12.26 and
18c: p < 0.02, F(2;6) = 8.06. The asterisk denotes
p < 0.05 and double asterisks denote p < 0.001,
which denote statistically significant differences
between treatments.
(C) TNFa but not FGF1 triggers IL6 release over
time. Two-way ANOVA reveals an effect of treat-
ment for R1 line and treatment and time for
18c line. P and F values are: IL-6 R1 (treatment):
p = 0.0035, F(2;18) = 7.88; IL-6 18c (treatment): p =
0.0003, F(2;18) = 111.7; and IL-6 18c (time): p =
0.01, F(2;18) = 5.86. The double asterisks denote
p < 0.001 and triple asterisks denote p < 0.0001,
which denote statistically significant differences
between treatments on day 7.
(D) hESC- and hiPSC-derived astrocytes have an immature reactive phenotype when cultured in FBS but can be triggered by single
factors to adopt a mature, quiescent phenotype (FGF1 or FGF2) or a reactive inflammatory one (TNFa or IL-1b).
See also Figure S6.NaOH solution, and radioactivity was measured using a scintillation counter.
Radioactive counts were normalized to total protein per culture well.
IL-6 ELISA
Astrocytes were treated for 1, 2, or 7 days with medium containing FBS, FGF1,
IL-1b, and TNFa. Medium was then harvested and used for the human IL-6
ELISA assay following manufacturer’s instructions (Invitrogen). Absorbance
was measured at 450 nm.
Statistical Analyses
For each independent experiment, duplicate sometimes triplicate cultures
were analyzed from twelve 10X fields per sample. All quantitative data were(C) Reduced abundance of NF1A-expressing cells in 80-day hESC- and hiPSC-
leads to cell aggregation. The scale bar represents 50 mm.
(D) Decrease in CX43 expression following treatment with FGF1 as compared
represents 75 mm.
(E) Two-fold increase in glutamate uptake in astrocytes treated with FGF1 but not
by Newman-Keuls multiple comparison posthoc test shows FGF1 treatment sign
cultures. TNFa treatment decreases uptake (*p < 0.05). Similar results were obta
(F) Absence of pronounced change in EAAT2 protein levels following FGF1 or TN
(G) qPCR analysis shows no major change in EAAT2 levels when astrocytes are
(H) qPCR analysis shows that hESC- and hiPSC-derived astrocytes strongly upre
FGF1 but not TNFa (mean ± SEM; n = 4 for R1 and n = 3 for 18c). One-way ANOVA
and 18c: p = 0.0019, F(2;6) = 21.94. The double asterisks denote p < 0.001, which
Similar changes are observed after replating of dissociated clumps (n = 1 for R1
See also Figures S4 and S5.
Cell Reanalyzed using Prism 5.0c (GraphPad). Sample groups were subjected
to one- or two-way ANOVA, with Newman-Keuls post hoc comparison
when all conditions are compared to each other and Dunnett posthoc compar-
ison when all columns are compared to control condition (e.g., FBS treatment).
The null hypothesis was rejected at 0.05 for all ANOVAs and post hoc tests.
See the Extended Experimental Procedures for more information.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Results, Extended Experimental
Procedures, and six figures and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.06.021.derived astrocytes following treatment for 7 days with FGF1 (50 ng/ml). FGF1
to TNFa. Results are typical of two independent experiments. The scale bar
TNFa. For line 18c, one-way ANOVA (p < 0.0001; F(2;12) = 48.58; n = 5) followed
ificantly (***p < 0.0001) promotes uptake over control- (FBS) and TNFa-treated
ined for line R1.
Fa treatment. Results are typical of four independent experiments.
cultured with FGF1 and TNFa.
gulate the alternative glutamate transporter EAAT1 7 days after treatment with
reveals an effect of treatment. P and F values are: R1: p = 0.0028, F(2;9) = 12.18
denotes statistically significant difference between treatments. Bottom panel:
and 18c).
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